CSF2 and melanoma: US FDA approval in 2015 was based on findings from the OPTiM phase III trial that demonstrated improved durable response rates in patients with stage IIIB-IVM1C unresectable melanoma who received intralesional T-VEC (16.3%) compared with GM-CSF (2.1%).6,7